Sugi Predict

Sugi Predict / Compounds / SCHEMBL1662738

SCHEMBL1662738

SCHEMBL1662738

O=C1c2ccccc2C(=O)N1c1cccc(O)c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 3/20 0.80
▸ NPC1 O15118 1/20 0.77
▸ RAB9A P51151 1/20 0.77
▸ NR1H3 Q13133 4/20 0.62
▸ KDM4E B2RXH2 1/20 0.62
▸ POLB P06746 1/20 0.62
▸ MEN1 O00255 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ ALDH1A1 P00352 3/20 0.58
▸ MAPT P10636 1/20 0.58
▸ NR1H2 P55055 1/20 0.56
▸ USP2 O75604 1/20 0.56
▸ TNNI3 P19429 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ TNNT2 P45379 1/20 0.56
▸ TNNC1 P63316 1/20 0.56
▸ TLR9 Q9NR96 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ SCN2A Q99250 2/20 0.56
▸ GRM5 P41594 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9588495 0.89 ESR1 (1.00) ESR1NPC1RAB9ANR1H3KDM4E
SCHEMBL15436400 0.87 ESR1 (0.84) ESR1NPC1RAB9ANR1H3KDM4E
SCHEMBL16521526 0.87 NPC1 (1.00) ESR1NPC1RAB9ANR1H3KDM4E
SCHEMBL759648 0.86 ESR1 (0.81) ESR1NPC1RAB9ANR1H3KDM4E
SCHEMBL725608 0.86 NR1H3 (0.67) ESR1NPC1RAB9ANR1H3MEN1
SCHEMBL9588487 0.84 NPC1 (0.66) ESR1NPC1RAB9ANR1H3KDM4E
SCHEMBL2631561 0.83 ESR1 (0.77) ESR1NPC1RAB9AKDM4EPOLB
SCHEMBL7360727 0.83 ESR1 (0.77) ESR1NPC1RAB9ANR1H3KDM4E
SCHEMBL9630819 0.83 ESR1 (0.90) ESR1NPC1RAB9AKDM4EPOLB
SCHEMBL31012107 0.83 ESR1 (0.90) ESR1NPC1RAB9AKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116496484-A Bisphenol type polyarylester with high heat resistance and high solubility and preparation method thereof 山东凯盛新材料股份有限公司 2023-07-28 — — CN disclosed
CN-116496484-A Bisphenol type polyarylester with high heat resistance and high solubility and preparation method thereof 山东凯盛新材料股份有限公司 2023-07-28 — — CN disclosed
US-8507635-B2 Modified polycarbonates having improved surface properties BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-13 — — US disclosed
EP-2313456-B1 MODIFIED POLYCARBONATES HAVING IMPROVED SURFACE PROPERTIES BAYER MATERIALSCIENCE AG (DE) 2013-01-30 — — EP disclosed
US-20110152470-A1 MODIFIED POLYCARBONATES HAVING IMPROVED SURFACE PROPERTIES BAYER MATERIALSCIENCE AG (DE) 2011-06-23 — — US disclosed
EP-2313456-A1 MODIFIED POLYCARBONATES HAVING IMPROVED SURFACE PROPERTIES Bayer MaterialScience AG (DE) 2011-04-27 — — EP disclosed
WO-2010015354-A1 MODIFIED POLYCARBONATES HAVING IMPROVED SURFACE PROPERTIES BAYER MATERIALSCIENCE AG (DE) 2010-02-11 — — WO disclosed
EP-1171127-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION TARGACEPT INC (US) 2005-09-14 — — EP disclosed
US-6627648-B1 Relevant nicotinic receptor subtypes to any significant degree. central nervous system disorders, are treated by administering to a patient in need thereof amine derivatives TARGACEPT, INC. 2003-09-30 — — US disclosed
US-6489349-B1 TREATING AN AUTOIMMUNE DISORDER WITH AN ALKYLAMINE SUBSTITUTED PYRIDINE TARGACEPT, INC. 2002-12-03 — — US disclosed
US-20010014691-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE TARGACEPT, INC. 2001-08-16 — — US disclosed
EP-1068186-A2 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE Targacept, Inc. (US) 2001-01-17 — — EP disclosed
US-6166048-A Pharmaceutical compositions for inhibition of cytokine production and secretion TARGACEPT, INC. (US) 2000-12-26 — — US disclosed
WO-2000071520-A2 ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS TARGACEPT, INC. (US) 2000-11-30 — — WO disclosed
WO-2000062767-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION TARGACEPT, INC. (US) 2000-10-26 — — WO disclosed
WO-1999051216-A2 3-PYRIDYLOXYALKYLAMINE OR ARYLOXYALKYLAMINE DERIVATIVES AS CHOLINERGIC AGONISTS R.J. REYNOLDS TOBACCO COMPANY (US) 1999-10-14 — — WO disclosed
EP-0161413-B1 WHOLLY AROMATIC POLYESTERS, PROCESS FOR THEIR PREPARATION AND SHAPED ARTICLES MADE THEREFROM HOECHST AKTIENGESELLSCHAFT (DE) 1989-01-18 — — EP disclosed
US-4661579-A Completely aromatic polyesters, a process for their preparation and corresponding shaped articles HOECHST AKTIENGESELLSCHAFT (DE) 1987-04-28 — — US disclosed
EP-0098012-B1 PROCESS FOR PREPARING (O-HYDROXYARYL)-METHANOLS BLASCHIM S.p.A. (IT) 1986-09-17 — — EP disclosed
US-4124375-A Substituted phthalimides for regulating the growth of plants MONSANTO COMPANY (US) 1978-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010014691-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE PNMT, HNMT, CHRM3 ESR1 3695/4885NPC1 460/4885RAB9A 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.